Context
The success of CAR T-cells is now indisputable for B-cell malignancies and has merited FDA and EMA approval in 2018.
The success of CAR T-cells is now indisputable for B-cell malignancies and has merited FDA and EMA approval in 2018.
Strategies targeting T-cell malignancies using CARTs remain challenging because of the shared expresion of target antigens between normal and malignant T-cells.
In carxall project we develop a next generation, allogeneic, off-the shelf CAR T cell products for R/R T-ALL patients.